{
  "docId": "019de074-640b-7614-ba57-564b2e029ae4",
  "docSlug": "dcb04f24edfbf49f2d2db8f66e75d66c",
  "documentTitle": "Sarissa Capital | Activist Presentation Deck | 109 slides",
  "authorId": "sarissa-capital",
  "authorName": "Sarissa Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 109,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a large red arrow to emphasize the negative financial performance.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-640b-7614-ba57-564b2e029ae4/11",
  "deckHref": "/decks/019de074-640b-7614-ba57-564b2e029ae4",
  "deckJsonHref": "/decks/019de074-640b-7614-ba57-564b2e029ae4.json",
  "deckAnchorHref": "/decks/019de074-640b-7614-ba57-564b2e029ae4#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.15,
        "x": 0.82,
        "y": 0.415
      },
      "kind": "callout",
      "text": "-$7.9bn -92% Total Return!*",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9084473-84ac-42ef-b1de-a09bb6cedd1a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.85,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Stock price performance from Jan 2018 to Dec 2022",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "153d5865-6a62-4275-9aed-1c4bb58ca2c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.15,
        "y": 0.25
      },
      "kind": "legend",
      "text": "Sept. 2018: REDUCE-IT Study Results Announced; Dec. 2019: FDA Vascepa label expanded",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5c4928f-7aca-4566-afd8-4679c1fac01f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "*Total return calculated between Dec 13, 2019 (date of FDA label expansion for Vascepa) and Jan 31, 2023",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da9c9fdb-98c3-467a-a8cf-c645090bcc3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Amarin shareholders have lost a lot of money since FDA approval for CVD prevention",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9057f1af-25c5-42c0-a392-7f04fbea6937",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "4b8781c0-43d4-4c7e-8d03-f3596f663a56",
      "evidence": "Contrasts the period before and after FDA approval to highlight value destruction.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 13,
      "from": 1,
      "beatId": "1d909efc-b320-48f6-8051-84e2a877a586",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The deck identifies the problem of Amarin's poor stock performance and destruction of shareholder value",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "bdcc96a2-e155-4176-af95-ba0775a34afb",
      "evidence": "The deck highlights the significant losses incurred by Amarin shareholders due to the company's poor performance",
      "position": 0,
      "objective": "What is the cost of inaction for Amarin shareholders?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}